TOKYOMEDIJAPAN MEDICAL REFERENCE
⌕ Search databaseOfficial source · PMDA / MHLW
Rx · Reference only · no online purchase

Leqembi (Lecanemab)

Leqembi / Lecanemab. Used to slow progression of mild cognitive impairment or mild dementia due to Alzheimer’s disease.

PMDAproduct-level source2026-09label updated2026-10-05site verified
レケンビ点滴静注200mg/500mg · 500 mg / 5 mL
Japanese product photo · 500 mg / 5 mL · エーザイ Medical
Main useUsed to slow progression of mild cognitive impairment or mild dementia due to Alzheimer’s disease.A brief overview of Japanese approved uses. Check the PMDA label below for product-specific conditions.
Japan product name
レケンビ点滴静注200mg/500mg
Brand
Leqembi
Generic name
Lecanemab
Japanese generic name
レカネマブ
Chinese name
仑卡奈单抗
Marketing authorization holder
エーザイ株式会社
Strengths
200 mg / 500 mg
Dosage form
IV infusion
Therapeutic area
Neurology
Regulatory status
Rx
Label updated
2026-09
TOKYO MEDI verified
2026-10-05
MEDICINE REFERENCE

Detailed product reference

Summaries refer to the listed Japanese product. Eligibility, adjustments and full risks depend on its label and strength; a clinician determines individual treatment.

01

Product overview

Leqembi targets aggregated soluble amyloid beta to slow early Alzheimer’s progression; it does not restore all lost cognition.

Read source section ↗
02

Mechanism of action

Promotes clearance of aggregated amyloid beta; amyloid-related imaging abnormalities (ARIA) require surveillance.

Read source section ↗
03

Japanese indications & eligibility

For mild cognitive impairment or mild dementia due to Alzheimer’s, with confirmed amyloid pathology and eligibility checks. This record covers IV products.

Read source section ↗
04

Administration & dose differences

The Japanese IV schedule is 10 mg/kg every two weeks, infused over approximately one hour.

Read source section ↗
05

Adverse effects & key risks

Key risks are ARIA-E, ARIA-H and infusion reactions. ARIA may be symptomatic or found only on imaging.

Read source section ↗
06

Contraindications & special populations

Contraindications include severe hypersensitivity and specified baseline edema or hemorrhagic MRI findings.

Read source section ↗
07

Drug interactions

Anticoagulants, antiplatelets and thrombolytics require careful hemorrhage-risk assessment.

Read source section ↗
08

Assessment & monitoring

Baseline and scheduled MRI, symptom-triggered imaging and cognitive/function follow-up are required.

Read source section ↗
09

Storage & handling

Refrigerate at 2–8°C; do not freeze or shake. Protect from light. The photo is the 500 mg IV vial.

Read source section ↗
10

Sources & verification

Product checked ·

Official source

These links go directly to PMDA records for this Japanese product. Professional and patient-facing sources are separated.